Company intelligence / Profile preview

Arginox Pharmaceuticals

Redwood City / Menlo Park, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Dissolved

Overview

The company’s lead asset, Tilarginine Acetate Injection, was evaluated in the pivotal Phase III TRIUMPH trial for cardiogenic shock following reperfusion after acute myocardial infarction. The trial aimed to assess whether inhibiting excess nitric oxide production could improve survival. The study achieved significant enrollment milestones but was ultimately terminated without regulatory approval. No commercial products are currently available from the company.

Therapeutic areas: HematologyCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Tilarginine Acetate

Commercial

Indications: Cardiogenic shock

Beyond the preview

Go deeper on Arginox Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arginox Pharmaceuticals.

Explore the full profile